Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Eupraxia Pharmaceuticals(EPRX) the EBIT is -17.75 M (-114%), Miss estimate;the EPS is -0.23 (+11.54%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.02B113.97%
-0.01B75.36%
-0.00B38.61%
EPSMiss expectations
-0.2311.54%
-0.228612.09%
-0.00140.55%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf